Methods for the treatment of breast cancer
Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
1. A method of treating breast cancer in a patient in need thereof, wherein the patient did not demonstrate a complete response, a partial response or stable disease for greater than six months during prior treatment with an aromatase inhibitor, the method comprising administering to the patient a combination therapy comprising entinostat and exemestane,
determining-the level of protein lysine acetylation at about 15 days after initiating said combination therapy,
comparing the level of protein lysine acetylation prior to administration of the combination therapy, and
continuing the combination therapy if patient has an increase in the level of protein lysine acetylation prior to administration of the combination therapy, wherein the combination therapy comprises 5 mg of entinostat and 25 mg of exemestane.
2. The method of claim 1 , wherein entinostat is administered weekly and the exemestane is administered daily.
3. The method of claim 1 , wherein the patient relapsed during treatment on or within 6 months of completion of a prior non-steroidal aromatase inhibitor given as adjuvant therapy.
4. The method of claim 1 , wherein the patient demonstrated progressive disease after at least 3 months treatment on prior non-steroidal aromatase inhibitor.
5. The method of claim 1 , wherein the breast cancer is ER-positive.
6. The method of claim 1 , wherein entinostat and exemestane are administered sequentially in either order or simultaneously.
7. The method of claim 1 , wherein entinostat and exemestane are administered simultaneously.
8. The method of claim 1 , wherein exemestane is administered first.
9. The method of claim 1 , wherein exemestane is administered daily and the entinostat is administered periodically.
10. The method of claim 1 , wherein entinostat is administered weekly and exemestane is administered daily.
11. The method of claim 1 , wherein entinostat is introduced to an ongoing exemestane course of therapy.
12. The method of claim 1 , wherein the increase is about 25%, about 50%, about 75%, about 100%, about 125%, or about 150%.
13. The method of claim 1 , wherein the protein lysine acetylation levels are obtained from a tissue sample selected from B-cells, T-cells, or monocytes.
14. The method of claim 1 , wherein the exemestane is administered daily.
15. The method of claim 1 , wherein entinostat is administered every 7 days of a 28-day cycle.
16. The method of claim 1 , wherein the combination therapy comprises oral administration of entinostat every 7 days of a 28-day cycle, and oral administration of exemestane every day.
17. The method of claim 1 , wherein determining the protein lysine acetylation level during the course of therapy is performed more than once.
18. The method of claim 1 , wherein determining the protein lysine acetylation level during the course of therapy is performed once.